Synthetic antibody targets prostate cancer
Last Updated: 2004-07-20 14:28:02 -0400 (Reuters Health)
By David Douglas
NEW YORK (Reuters Health) - Most prostate cancers at first are driven by male hormones -- androgens -- but they then become androgen independent, often spreading to other areas of the body. At this stage, treatment is difficult, but a new "smart drug" holds promise.
Researchers have developed an antibody, J591, that homes in on a specific molecule on prostate cancer cells. With a radioactive isotope attached, the antibody produced an anti-tumor effect in an early-stage (phase I) trial involving men with androgen-independent prostate cancer.
Article: http://www.reutershealth.com/archive/2004/07/20/eline/links/20040720elin023.html